معرفی
Steven J. Sucheck, Ph.D., is a Professor and Chair of the Department of Chemistry & Biochemistry at the University of Toledo within the College of Natural Sciences and Mathematics. His research program focuses on bioorganic chemistry and the development of small molecules for therapeutic and chemical biology applications, particularly against Mycobacterium tuberculosis (Mtb) and in immunotherapeutic vaccine design.
Currently, Dr. Sucheck leads three NIH-funded research initiatives: (1) Synthesis of enzyme inhibitors targeting trehalose utilization pathways in Mtb, (2) Development of marine natural product derivatives as anti-TB agents, and (3) Creation of antibody-recruiting molecules (ARMs) to enhance immunotherapies for cancer and bacterial infections. His work bridges synthetic organic chemistry with microbiology and immunology, emphasizing collaborative interdisciplinary approaches.
- B.S., University of Toledo (1992)
- Ph.D., University of Virginia (1998)
- NIH Postdoctoral Fellow, The Scripps Research Institute (1998-2000)
- Industry roles at Optimer Pharmaceuticals (2000-2005)
Publications highlight his expertise in glycoside hydrolase inhibition, marine compound evaluation against dormant Mtb, and vaccine adjuvant development. His team has reported significant advances in targeting Mtb enzymes like Ag85C and GlgE, while exploring L-rhamnose-based immunomodulation strategies.
Scientific Contributions
- NIH-funded anti-TB research
- Development of antibody-recruiting molecules (ARMs)
- Structural studies of enzyme-inhibitor complexes (X-ray crystallography)
- Novel synthetic methods for oligosaccharides and glycoconjugates
